JP2013521304A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013521304A5 JP2013521304A5 JP2012556213A JP2012556213A JP2013521304A5 JP 2013521304 A5 JP2013521304 A5 JP 2013521304A5 JP 2012556213 A JP2012556213 A JP 2012556213A JP 2012556213 A JP2012556213 A JP 2012556213A JP 2013521304 A5 JP2013521304 A5 JP 2013521304A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- amount
- subject
- laquinimod
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 claims description 29
- 229960004577 laquinimod Drugs 0.000 claims description 29
- 239000008194 pharmaceutical composition Substances 0.000 claims description 28
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 26
- 229960000485 methotrexate Drugs 0.000 claims description 26
- 150000003839 salts Chemical class 0.000 claims description 21
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 16
- 208000024891 symptom Diseases 0.000 claims description 15
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 14
- 229940109239 creatinine Drugs 0.000 claims description 8
- 210000002700 urine Anatomy 0.000 claims description 8
- 230000000737 periodic effect Effects 0.000 claims description 7
- 102000009027 Albumins Human genes 0.000 claims description 6
- 108010088751 Albumins Proteins 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 201000001474 proteinuria Diseases 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 3
- 208000006386 Bone Resorption Diseases 0.000 claims description 2
- 206010007710 Cartilage injury Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims description 2
- 241001111421 Pannus Species 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 230000024279 bone resorption Effects 0.000 claims description 2
- 238000009535 clinical urine test Methods 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 229960001334 corticosteroids Drugs 0.000 claims description 2
- 231100000433 cytotoxic Toxicity 0.000 claims description 2
- 230000001472 cytotoxic effect Effects 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 150000002344 gold compounds Chemical class 0.000 claims description 2
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims description 2
- 229960004171 hydroxychloroquine Drugs 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 150000003873 salicylate salts Chemical class 0.000 claims description 2
- 239000013049 sediment Substances 0.000 claims description 2
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims description 2
- 229960001940 sulfasalazine Drugs 0.000 claims description 2
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 230000002485 urinary effect Effects 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims 3
- 230000037396 body weight Effects 0.000 claims 2
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 27
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33937510P | 2010-03-03 | 2010-03-03 | |
| US61/339,375 | 2010-03-03 | ||
| PCT/US2011/026885 WO2011109531A1 (en) | 2010-03-03 | 2011-03-02 | Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013521304A JP2013521304A (ja) | 2013-06-10 |
| JP2013521304A5 true JP2013521304A5 (cg-RX-API-DMAC7.html) | 2014-04-17 |
| JP5819328B2 JP5819328B2 (ja) | 2015-11-24 |
Family
ID=44531858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012556213A Expired - Fee Related JP5819328B2 (ja) | 2010-03-03 | 2011-03-02 | ラキニモドとメトトレキセートとの組合せによる関節リウマチの治療 |
Country Status (22)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101440982B1 (ko) * | 2005-10-19 | 2014-09-17 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드 나트륨의 결정 및 이의 제조방법 |
| ATE532515T1 (de) | 2006-06-12 | 2011-11-15 | Teva Pharma | Stabile laquinimod-zubereitungen |
| RS53199B (sr) | 2007-12-20 | 2014-06-30 | Teva Pharmaceutical Industries Ltd. | Stabilni preparati lakvinimoda |
| EP2337779B1 (en) * | 2008-09-03 | 2017-04-19 | Teva Pharmaceutical Industries Ltd. | 2-oxo-1,2-dihydro-quinoline modulators of immune function |
| AU2010260455A1 (en) * | 2009-06-19 | 2012-02-02 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with laquinimod |
| JP5882208B2 (ja) * | 2009-07-30 | 2016-03-09 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドによるクローン病の治療 |
| RS55071B1 (sr) | 2009-08-10 | 2016-12-30 | Teva Pharma | Tretman poremećaja koji su u vezi sa bdnf primenom lakvinimoda |
| BR112012021905A2 (pt) * | 2010-03-03 | 2015-09-29 | Teva Pharma | tratamento de nefrite lúpica usando laquinimod |
| MX2013000333A (es) | 2010-07-09 | 2013-02-26 | Teva Pharma | N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinoli na-3-carboxamida deuterada, sales y usos de la misma. |
| WO2013055907A1 (en) | 2011-10-12 | 2013-04-18 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
| MX2014009373A (es) | 2012-02-03 | 2014-08-27 | Teva Pharma | Uso de laquinimod para tratar pacientes con enfermedad de crohn que fallaron en la terapia de anti-tnfa de primera linea. |
| CN104114172A (zh) | 2012-02-16 | 2014-10-22 | 泰华制药工业有限公司 | N-乙基-n-苯基-1,2-二氢-4,5-二-羟基-1-甲基-2-氧代-3-喹啉甲酰胺、其制备和用途 |
| TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺 |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| EP2916915A4 (en) | 2012-11-07 | 2016-06-22 | Teva Pharma | LAQUINIMOD AMINE SALTS |
| EP2970129A2 (en) | 2013-03-14 | 2016-01-20 | Teva Pharmaceutical Industries Ltd. | Crystals of laquinimod sodium and improved process for the manufacture thereof |
| US20160038435A1 (en) | 2013-03-14 | 2016-02-11 | Teva Pharmaceutical Industries Ltd. | Transdermal formulations of laquinimod |
| WO2015168103A1 (en) | 2014-04-29 | 2015-11-05 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
| CN115281149A (zh) * | 2021-05-12 | 2022-11-04 | 四川大学华西医院 | 一种临床前类风湿关节炎(Pre-RA)小鼠模型 |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2340735A1 (fr) | 1976-02-11 | 1977-09-09 | Roussel Uclaf | Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament |
| IE52670B1 (en) | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
| US5540934A (en) | 1994-06-22 | 1996-07-30 | Touitou; Elka | Compositions for applying active substances to or through the skin |
| US5912349A (en) | 1997-01-31 | 1999-06-15 | Pharmacia & Upjohn Company | Process for the preparation of roquinimex |
| US6696407B1 (en) | 1997-03-21 | 2004-02-24 | The Regents Of The University Of California | Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF |
| US6077851A (en) * | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| US6121287A (en) | 1998-07-15 | 2000-09-19 | Active Biotech Ab | Quinoline derivatives |
| SE9802550D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| US6133285A (en) | 1998-07-15 | 2000-10-17 | Active Biotech Ab | Quinoline derivatives |
| RS51019B (sr) | 1999-10-25 | 2010-10-31 | Active Biotech Ab. | Lekovi za lečenje malignih tumora |
| EP1365794A2 (en) | 2000-07-21 | 2003-12-03 | Lue, Tom | Prevention and treatment of sexual arousal disorders |
| US6307050B1 (en) | 2000-08-29 | 2001-10-23 | R. T. Alamo Venture I Llc | Method of synthesizing flosequinan from 4-fluoroanthranilic acid |
| US7560557B2 (en) | 2002-06-12 | 2009-07-14 | Active Biotech Ag | Process for the manufacture of quinoline derivatives |
| SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| US6875869B2 (en) | 2002-06-12 | 2005-04-05 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| US20070292461A1 (en) | 2003-08-04 | 2007-12-20 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| CA2528723A1 (en) * | 2003-06-25 | 2005-01-06 | Elan Pharmaceuticals, Inc. | Methods and compositions for treating rheumatoid arthritis |
| US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
| US8314124B2 (en) | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
| SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| US20060004019A1 (en) | 2004-04-01 | 2006-01-05 | Ivan Lieberburg | Steroid sparing agents and methods of using same |
| EP1796710A4 (en) | 2004-09-02 | 2010-05-26 | Teva Pharma | THERAPY COMBINED WITH GLATIRAMER ACETATE AND N-ACETYLCYSTEINE TO TREAT MULTIPLE SCLEROSIS |
| US7560100B2 (en) | 2004-09-09 | 2009-07-14 | Yeda Research And Development Co., Ltd. | Mixtures of polypeptides, compositions containing and processes for preparing same, for treating neurodegenerative diseases |
| US20060205822A1 (en) | 2004-12-22 | 2006-09-14 | Forest Laboratories, Inc. | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect |
| JP5905184B2 (ja) | 2005-10-13 | 2016-04-20 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッドＨｕｍａｎ Ｇｅｎｏｍｅ Ｓｃｉｅｎｃｅｓ， Ｉｎｃ． | 自己抗体陽性疾患を有する患者の処置に使用するための方法および組成物 |
| US9168286B2 (en) | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
| KR101440982B1 (ko) | 2005-10-19 | 2014-09-17 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드 나트륨의 결정 및 이의 제조방법 |
| RS52229B (sr) * | 2005-10-26 | 2012-10-31 | Merck Serono Sa. | Derivati sulfonamida i njihova upotreba za modulaciju metaloproteinaza |
| US20080108641A1 (en) | 2006-02-08 | 2008-05-08 | Ajami Alfred M | Compounds for treating inflammatory disorders, demyelinating disdorders and cancers |
| US8367629B2 (en) | 2006-02-14 | 2013-02-05 | Noxxon Pharma Ag | MCP-1 binding nucleic acids and use thereof |
| WO2007100763A2 (en) | 2006-02-28 | 2007-09-07 | Elan Pharmaceuticals, Inc. | Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds |
| ES2752137T3 (es) | 2006-02-28 | 2020-04-03 | Biogen Ma Inc | Métodos para tratar enfermedades inflamatorias y autoinmunes con natalizumab |
| CA2644110A1 (en) | 2006-03-03 | 2007-09-13 | Elan Pharmaceuticals, Inc. | Methods of treating inflammatory and autoimmune diseases with natalizumab |
| US9399061B2 (en) | 2006-04-10 | 2016-07-26 | Abbvie Biotechnology Ltd | Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis |
| WO2007139887A2 (en) | 2006-05-22 | 2007-12-06 | Cargill, Incorporated | Methods for treating bone or joint inflammation |
| WO2007146331A1 (en) | 2006-06-12 | 2007-12-21 | Teva Pharmaceutical Industries, Ltd. | Tannate salt form of polypeptide mixtures, their preparation and use |
| ATE532515T1 (de) | 2006-06-12 | 2011-11-15 | Teva Pharma | Stabile laquinimod-zubereitungen |
| WO2008021368A2 (en) | 2006-08-11 | 2008-02-21 | The Johns Hopkins University | Compositions and methods for neuroprotection |
| JP2010513518A (ja) | 2006-12-19 | 2010-04-30 | メリマック ファーマシューティカルズ インコーポレーティッド | 多発性硬化症治療ためのα‐フェトプロテインおよび免疫調節作用物質の同時投与方法 |
| US20100136125A1 (en) | 2006-12-28 | 2010-06-03 | Jacobus Pharmaceutical Company, Inc. | Method of treating inflammatory bowel disease |
| PL2187882T3 (pl) | 2007-07-11 | 2013-05-31 | Medicinova Inc | Leczenie postępującej choroby neurodegeneracyjnej ibudilastem |
| RS53199B (sr) | 2007-12-20 | 2014-06-30 | Teva Pharmaceutical Industries Ltd. | Stabilni preparati lakvinimoda |
| EP2337779B1 (en) | 2008-09-03 | 2017-04-19 | Teva Pharmaceutical Industries Ltd. | 2-oxo-1,2-dihydro-quinoline modulators of immune function |
| BRPI0920927A2 (pt) | 2008-11-13 | 2019-09-24 | Link Medicine Corp | derivados de azaquinolinona e usos dos mesmos |
| AU2010260455A1 (en) | 2009-06-19 | 2012-02-02 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with laquinimod |
| JP5882208B2 (ja) | 2009-07-30 | 2016-03-09 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドによるクローン病の治療 |
| RS55071B1 (sr) | 2009-08-10 | 2016-12-30 | Teva Pharma | Tretman poremećaja koji su u vezi sa bdnf primenom lakvinimoda |
| MX342001B (es) | 2010-03-03 | 2016-09-09 | Teva Pharmaceutical Ind Ltd * | Tratamiento de artritis por lupus usando laquinimod. |
| BR112012021905A2 (pt) | 2010-03-03 | 2015-09-29 | Teva Pharma | tratamento de nefrite lúpica usando laquinimod |
| MX2013000333A (es) | 2010-07-09 | 2013-02-26 | Teva Pharma | N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinoli na-3-carboxamida deuterada, sales y usos de la misma. |
| CN102985090B (zh) | 2010-07-09 | 2014-11-26 | 泰华制药工业有限公司 | 5-氯-4-羟基-1-甲基-2-氧代-n-苯基-1,2-二氢喹啉-3-甲酰胺、其盐和用途 |
| SG10201509831XA (en) | 2010-12-07 | 2015-12-30 | Teva Pharma | Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients |
| EP2736336A4 (en) | 2011-07-28 | 2015-03-04 | Teva Pharma | TREATMENT OF MULTIPLE SCLEROSIS WITH A COMBINATION OF LAQUINIMOD AND INTERFERON-BETA |
| KR20140054166A (ko) | 2011-07-28 | 2014-05-08 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드 및 글라티라머 아세테이트의 병용에 의한 다발성 경화증의 치료 |
-
2011
- 2011-03-02 CN CN2011800121091A patent/CN102781240A/zh active Pending
- 2011-03-02 BR BR112012022187A patent/BR112012022187A2/pt not_active IP Right Cessation
- 2011-03-02 KR KR1020127025006A patent/KR20130014523A/ko not_active Ceased
- 2011-03-02 PH PH1/2012/501740A patent/PH12012501740A1/en unknown
- 2011-03-02 CN CN201610240474.2A patent/CN105796556A/zh active Pending
- 2011-03-02 SG SG2012063491A patent/SG183513A1/en unknown
- 2011-03-02 ES ES11751300.2T patent/ES2476368T3/es active Active
- 2011-03-02 US US13/039,188 patent/US8501766B2/en not_active Expired - Fee Related
- 2011-03-02 SI SI201130210T patent/SI2542079T1/sl unknown
- 2011-03-02 PT PT117513002T patent/PT2542079E/pt unknown
- 2011-03-02 JP JP2012556213A patent/JP5819328B2/ja not_active Expired - Fee Related
- 2011-03-02 EA EA201290860A patent/EA201290860A1/ru unknown
- 2011-03-02 EP EP11751300.2A patent/EP2542079B1/en active Active
- 2011-03-02 WO PCT/US2011/026885 patent/WO2011109531A1/en not_active Ceased
- 2011-03-02 NZ NZ602478A patent/NZ602478A/en not_active IP Right Cessation
- 2011-03-02 PE PE2012001383A patent/PE20130690A1/es not_active Application Discontinuation
- 2011-03-02 AU AU2011223697A patent/AU2011223697B2/en not_active Ceased
- 2011-03-02 DK DK11751300.2T patent/DK2542079T3/da active
- 2011-03-02 CA CA2791709A patent/CA2791709A1/en not_active Abandoned
- 2011-03-02 MX MX2012010066A patent/MX2012010066A/es active IP Right Grant
-
2012
- 2012-08-31 CL CL2012002424A patent/CL2012002424A1/es unknown
- 2012-09-17 CO CO12159942A patent/CO6630085A2/es unknown
- 2012-09-21 ZA ZA2012/07128A patent/ZA201207128B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013521304A5 (cg-RX-API-DMAC7.html) | ||
| ES3001196T3 (es) | Nuevo uso de una combinación de un bloqueador del receptor de la angiotensina (ARB) con un inhibidor de la endopeptidasa neutra (NEPI) | |
| US20250241919A1 (en) | Combination of active agents for the treatment of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) | |
| JP2010518122A5 (cg-RX-API-DMAC7.html) | ||
| JP5753152B2 (ja) | アミロイドーシスを処置するための製剤および方法 | |
| JP2015512406A5 (cg-RX-API-DMAC7.html) | ||
| CN101384254A (zh) | 能够增强gabaa能神经传递的化合物用于治疗炎性疾病的用途 | |
| JP2020508339A5 (cg-RX-API-DMAC7.html) | ||
| JP2017537164A (ja) | リンパ腫の治療に使用されるヒストン脱アセチル化酵素阻害剤とベンダムスチンとの組み合わせ | |
| JP2014532726A5 (cg-RX-API-DMAC7.html) | ||
| Huddleston et al. | Emerging strategies for treating gout | |
| CN109069467B (zh) | 肌生成抑制蛋白拮抗剂的用途、含有它们的组合及其用途 | |
| TW201330852A (zh) | 具有高度腎功能障礙之血栓栓塞症患者之血栓栓塞症之預防治療劑 | |
| JP2020519576A5 (cg-RX-API-DMAC7.html) | ||
| WO2014141295A2 (en) | Treatment and prophylaxis of kidney diseases | |
| CN105358148A (zh) | 用于治疗肾小球疾病的losmapimod | |
| JP2007512381A5 (cg-RX-API-DMAC7.html) | ||
| JP2024520150A (ja) | １－（３－シアノ－１－イソプロピル－インドール－５－イル）ピラゾール－４－カルボン酸を含む薬学的組成物 | |
| JP2013510866A (ja) | 組み合わせたチボザニブおよびテムシロリムス | |
| MX2011010030A (es) | Medicamento novedoso para el tratamiento del deterioro cognitivo. | |
| JP2022515615A (ja) | 慢性炎症性腸疾患の治療のためのｐａｒ－１アンタゴニストの使用 | |
| AU2019204289B2 (en) | Methods and compositions for the treatment of pain and/or inflammation | |
| CZ2003234A3 (cs) | 2-Aryl-8-oxodihydropurinové deriváty jako léčivo | |
| EA048070B1 (ru) | Способы лечения кожной красной волчанки | |
| Van Dyke et al. | Drugs Used in Gout |